Completion rates for the human papillomavirus (HPV) vaccine series across both genders continue to remain alarmingly low nearly seven years after its introduction, suggesting that better patient education and increased public vaccine financing programs are needed, according to new research from the University of Texas Medical Branch (UTMB).
The researchers report "startling" trends in a series of three separate studies published in Cancer, Human Vaccines & Immunotherapeutics and Vaccine.
Using data from the 2010 National Health Interview Survey, an annual cross-sectional survey tracking more than 27,000 adults in the US., researchers found:
Analyzing private insurance claims from 2006-2009:
"This is the first generation with the opportunity to be vaccinated against the devastating cancers associated with HPV, but the majority are missing the opportunity," said lead author Dr. Abbey Berenson, professor, Department of Obstetrics and Gynecolo
|Contact: Lauren Whisenant|
University of Texas Medical Branch at Galveston